An open-label pilot study to investigate the efficacy of apremilast in the treatment of central centrifugal cicatricial alopecia (CCCA)

ID#: NCT02643979

Age: 18 years - 66+

Gender: Female

Healthy Subjects: No

Study Phase: Phase 4

Recruitment Status: Recruiting

Start Date: May 31, 2018

End Date: October 15, 2019

Contact Information:
Ingrid Sanabria-Gonzalez
212-523-3812
Summary:

"The purpose of this study is to see if the use of apremilast has an effect on the symptoms and progression of central centrifugal cicatricial alopecia (CCCA). Apremilast is an oral PDE4 inhibitor that has anti-inflammatory properties. It inhibits several substances involved in inflammation within the body. Apremilast is FDA approved for the treatment of another condition, moderate to severe psoriasis and psoriatic arthritis. Apremilast is not FDA approved for the treatment of CCCA.

Eligibility:



Inclusion Criteria:

- Females of African ancestry >18 years of age at the time of screening

- Clinical diagnosis of mild to moderate CCCA (central centrifugal cicatricial alopecia)

Find a Clinical Trial Find Cancer Clinical Trials